<p>Polaryx Therapeutics, Inc.（纳斯达克代码：PLYX - 获取免费报告）在周二的交易中上涨了 4.9%。该公司的股价最高达到 6.49 美元，最后交易价为 6.47 美元。在交易中共成交 141,137 股，较平均交易量 2,268,150 股下降了 94%。该股票此前收盘价为 6.17 美元。</p>
<p>获取 <strong>Polaryx Therapeutics</strong> 的提醒：</p>
<h2>分析师评级上调和下调</h2>
<p>另外，Maxim Group 在 2 月 27 日星期五发布的报告中开始覆盖 Polaryx Therapeutics。他们对该股票设定了 “买入” 评级和 10.00 美元的目标价。一位投资分析师对该股票给予了买入评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “买入”，平均目标价为 10.00 美元。</p>
<p><strong>查看我们对 PLYX 的最新股票分析</strong></p>
<h2>Polaryx Therapeutics 股票上涨 4.9%</h2>
<h2>Polaryx Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>我们是一家临床阶段的生物技术公司，致力于发现、开发和商业化新型的疾病修饰疗法，针对罕见的儿童溶酶体储存疾病（“LSDs”）。我们的治疗理念集中在提供安全、有效且以患者为中心的治疗，解决这些灾难性疾病的潜在病理生理学及其显著的未满足需求。我们采用多模式的方法，整合小分子疗法，包括联合疗法和基因疗法，使我们能够潜在地解决 LSDs 的遗传和下游病理特征。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Polaryx Therapeutics</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Polaryx Therapeutics 吗？</h2>
<p>在考虑 Polaryx Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师，以及他们每天向客户推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Polaryx Therapeutics 并不在名单上。</p>
<p>虽然 Polaryx Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

PLYX

<p>Polaryx Therapeutics（纳斯达克代码：PLYX）股价上涨 4.9%，至 6.47 美元，尽管交易量大幅下降。Maxim Group 对其进行了覆盖，给予 “买入” 评级，目标价为 10.00 美元。目前，该股票在分析师中持有平均 “买入” 评级，目标价为 10.00 美元。该公司专注于开发针对罕见儿童溶酶体贮积病的治疗方案</p>

<p>Shares of Polaryx Therapeutics, Inc. (NASDAQ:PLYX - Get Free Report) traded up 4.9% during trading on Tuesday . The company traded as high as $6.49 and last traded at $6.47. 141,137 shares were traded during trading, a decline of 94% from the average session volume of 2,268,150 shares. The stock had previously closed at $6.17.</p>
<div class="lb-trans"><p>Polaryx Therapeutics, Inc.（纳斯达克代码：PLYX - 获取免费报告）在周二的交易中上涨了 4.9%。该公司的股价最高达到 6.49 美元，最后交易价为 6.47 美元。在交易中共成交 141,137 股，较平均交易量 2,268,150 股下降了 94%。该股票此前收盘价为 6.17 美元。</p>
</div><p>Get <strong>Polaryx Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Polaryx Therapeutics</strong> 的提醒：</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级上调和下调</h2>
</div><p>Separately, Maxim Group started coverage on Polaryx Therapeutics in a report on Friday, February 27th. They set a &#34;buy&#34; rating and a $10.00 target price on the stock. One investment analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has an average rating of &#34;Buy&#34; and an average target price of $10.00.</p>
<div class="lb-trans"><p>另外，Maxim Group 在 2 月 27 日星期五发布的报告中开始覆盖 Polaryx Therapeutics。他们对该股票设定了 “买入” 评级和 10.00 美元的目标价。一位投资分析师对该股票给予了买入评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “买入”，平均目标价为 10.00 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on PLYX</strong></p>
<div class="lb-trans"><p><strong>查看我们对 PLYX 的最新股票分析</strong></p>
</div><h2>Polaryx Therapeutics Stock Up 4.9%</h2>
<div class="lb-trans"><h2>Polaryx Therapeutics 股票上涨 4.9%</h2>
</div><h2>Polaryx Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Polaryx Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>We are a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs.</p>
<div class="lb-trans"><p>我们是一家临床阶段的生物技术公司，致力于发现、开发和商业化新型的疾病修饰疗法，针对罕见的儿童溶酶体储存疾病（“LSDs”）。我们的治疗理念集中在提供安全、有效且以患者为中心的治疗，解决这些灾难性疾病的潜在病理生理学及其显著的未满足需求。我们采用多模式的方法，整合小分子疗法，包括联合疗法和基因疗法，使我们能够潜在地解决 LSDs 的遗传和下游病理特征。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Polaryx Therapeutics</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Polaryx Therapeutics</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Polaryx Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Polaryx Therapeutics 吗？</h2>
</div><p>Before you consider Polaryx Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Polaryx Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Polaryx Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师，以及他们每天向客户推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Polaryx Therapeutics 并不在名单上。</p>
</div><p>While Polaryx Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Polaryx Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Polaryx Therapeutics（NASDAQ:PLYX）股价上涨 4.9% - 现在是买入的好时机吗？